Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 7/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837205 | 0.85 | SCN9A (0.58) | HSD17B1MAPTSMN1; SMN2KIF11SCN9A | |
| SCHEMBL11544490 | 0.85 | SCN9A (0.58) | HSD17B1MAPTSMN1; SMN2KIF11SCN9A | |
| SCHEMBL385758 | 0.84 | HSP90AA1 (0.58) | HSD17B1HSD17B2MAPTSMN1; SMN2HSP90AA1 | |
| SCHEMBL29911026 | 0.79 | ESR2 (0.77) | HSD17B1ESR2HSD17B2HDAC2ESR1 | |
| SCHEMBL28202577 | 0.79 | ESR2 (0.77) | HSD17B1ESR2HSD17B2HDAC2ESR1 | |
| SCHEMBL278316 | 0.79 | ESR2 (0.77) | HSD17B1ESR2HSD17B2HDAC2ESR1 | |
| SCHEMBL2560422 | 0.79 | XDH (0.56) | HSD17B1MAPTSMN1; SMN2KIF11TSHR | |
| SCHEMBL9150363 | 0.78 | KDM4E (0.71) | HSD17B1ESR2HSD17B2MAPTSMN1; SMN2 | |
| SCHEMBL9649870 | 0.78 | HSD17B1 (0.62) | HSD17B1MAPTSMN1; SMN2HDAC2ESR1 | |
| Methane SCHEMBL10594573 | 0.77 | ESR2 (0.74) | HSD17B1ESR2HSD17B2HDAC2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-5397504-A | Liquid crystal | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 1995-03-14 | — | — | US | disclosed |
| EP-0315701-B1 | BIPHENYL COMPOUND | KANTO KAGAKU (JP) | 1993-12-29 | — | — | EP | disclosed |
| EP-0315701-A1 | BIPHENYL COMPOUND | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885ESR2 133/4885HSD17B2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.